DGIdb - BINIMETINIB Drug Record

BINIMETINIB chembl:CHEMBL3187723 ApprovedAntineoplastic

Alternate Names:

BINIMETINIB
MEKTOVI
ARRY-438162
ARRY 438162
NVP-MEK162
MEK-162
ARRY-162
MEK162
ARRY 162
chembl:CHEMBL3187723
pubchem.compound:10288191
drugbank:11967
chemidplus:606143-89-9

Drug Info:

Notes	allosteric inhibitor
Drug Class	Kinase Inhibitors
FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antiinflammatory agent,DMARD,antineoplastic agent
Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational
Drug Categories	antineoplastic agents
Drug Categories	antineoplastic and immunomodulating agents
Drug Categories	cytochrome p-450 cyp1a2 substrates
Drug Categories	cytochrome p-450 cyp2c19 substrates
Drug Categories	cytochrome p-450 substrates
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	map kinase kinase 1, antagonists & inhibitors
Drug Categories	map kinase kinase 2, antagonists & inhibitors
Drug Categories	p-glycoprotein substrates with narrow therapeutic index
Drug Categories	protein kinase inhibitors
Drug Categories	ugt1a1 substrates
Drug Categories	ugt1a1 substrates with narrow therapeutic index

(13 More Sources)

Publications:

Woodfield et al., 2016, Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression., BMC Cancer
Niessner et al., 2016, PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo., Clin. Cancer Res.
Ascierto et al., 2013, MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study., Lancet Oncol.
Kopetz S et al., 2019, Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer., N Engl J Med
Bendell et al., 2017, A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor., Br. J. Cancer
Dummer R et al., 2018, Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol
Herkert et al., 2016, Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition., Cancer Res.
Gao Y et al., 2019, V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer., Cancer Discov
Koelblinger P et al., 2017, A review of binimetinib for the treatment of mutant cutaneous melanoma., Future Oncol
Raja et al., 2015, Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer., Mol. Cancer Ther.
Kiessling et al., 2015, Mutant HRAS as novel target for MEK and mTOR inhibitors., Oncotarget
Thumar et al., 2014, MEK targeting in N-RAS mutated metastatic melanoma., Mol. Cancer
Dummer et al., 2017, Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial., Lancet Oncol.
Yan J et al., 2018, Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor., Eur J Cancer
Morgan et al., 2001, Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling., Blood
Gritsman et al., 2014, Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α., J. Clin. Invest.
Vu et al., 2016, Targeting mutant NRAS signaling pathways in melanoma., Pharmacol. Res.
Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
Kiessling et al., 2016, Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma., PLoS ONE
Monk BJ et al., 2020, MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum., J Clin Oncol
Hamidi et al., 2014, KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition., Br. J. Cancer
Dhawan et al., 2016, Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling., Nature
Kim et al., 2016, Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer., Mol. Cancer Res.
Lee et al., 2016, Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models., Oncotarget
Carita et al., 2016, Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma., Oncotarget
Chen et al., 2014, Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations., Oncogene

BINIMETINIB MAP2K7

Interaction Score: 0.86

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial TTD
BINIMETINIB GNA11

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MEK162 + AEB071

Indication/Tumor Type uveal melanoma

Response Type sensitive

PMIDs:
24141786 27507190

Sources:
JAX-CKB
BINIMETINIB NRAS

Interaction Score: 0.75

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BYL719 + MEK162

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

PMIDs:
24588908 28284557 27307593 23414587 29245078 28152546 11238126 24569456 26987942 28514312 26821351

Sources:
OncoKB JAX-CKB CIViC
BINIMETINIB MAP2K2

Interaction Score: 0.48

Interaction Types & Directionality:

allosteric modulator

inhibitor (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name ARRY-162

Specific Action of the Ligand Negative

PMIDs:
28587477

Sources:
ClearityFoundationClinicalTrial MyCancerGenomeClinicalTrial TdgClinicalTrial DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions
BINIMETINIB MAP3K1

Interaction Score: 0.47

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
28587477

Sources:
DrugBank
BINIMETINIB MAP2K5

Interaction Score: 0.43

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial
BINIMETINIB GNAQ

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MEK162 + AEB071

Indication/Tumor Type uveal melanoma

Response Type predicted – sensitive

PMIDs:
27507190

Sources:
JAX-CKB
BINIMETINIB MAP2K1

Interaction Score: 0.38

Interaction Types & Directionality:

allosteric modulator

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 1 inhibitor

Direct Interaction yes

Specific Action of the Ligand Negative

PMIDs:
31227518

Sources:
ClearityFoundationClinicalTrial MyCancerGenomeClinicalTrial TdgClinicalTrial CIViC MyCancerGenome GuideToPharmacology ChemblInteractions
BINIMETINIB MAP2K4

Interaction Score: 0.37

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial
BINIMETINIB MAP2K3

Interaction Score: 0.37

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial
BINIMETINIB NF1

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26925841

Sources:
ClearityFoundationBiomarkers CIViC
BINIMETINIB MAP2K6

Interaction Score: 0.32

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial
BINIMETINIB BRAF

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Encorafenib + Binimetinib

combination therapy Encorafenib + Binimetinib + Cetuximab

Evidence Type Actionable

PMIDs:
27307593 23414587 31566309 28152546 29573941 26577700

Sources:
ClearityFoundationBiomarkers OncoKB FDA PharmGKB JAX-CKB CIViC
BINIMETINIB APC

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type no benefit

Evidence Type Actionable

Approval Status Preclinical

PMIDs:
26206338

Sources:
JAX-CKB
BINIMETINIB KRAS

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung adenocarcinoma

Response Type decreased response

Approval Status Preclinical - Cell culture

PMIDs:
32822286 26206338 28152546 25167228 27556948 27422710 27167191

Sources:
ClearityFoundationBiomarkers OncoKB JAX-CKB CIViC
BINIMETINIB HRAS

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type urinary bladder cancer

Response Type predicted – sensitive

Indication/Tumor Type Advanced Solid Tumor

PMIDs:
26544513

Sources:
JAX-CKB CIViC
BINIMETINIB UGT1A1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA PharmGKB
BINIMETINIB ATM

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Clinical Study

PMIDs:
28514312

Sources:
JAX-CKB
BINIMETINIB IL6

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DrugBank
BINIMETINIB PTEN

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BYL719 + MEK162

Indication/Tumor Type melanoma

Response Type no benefit

PMIDs:
26206338 26577700

Sources:
JAX-CKB
BINIMETINIB IL1B

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DrugBank
BINIMETINIB TNF

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DrugBank

DrugBank: DB11967
- Version: 5.1.7
Alternate Names:

BINIMETINIB DrugBank Drug Name

606143-89-9 CAS Number

Mektovi Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Koelblinger P et al., 2017, A review of binimetinib for the treatment of mutant cutaneous melanoma., Future Oncol
MyCancerGenome: MEK162
- Version: 20-Jun-2017
Alternate Names:

MEK162 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Notes allosteric inhibitor

Publications:
TdgClinicalTrial: ARRY-162
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiinflammatory agent,DMARD,antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:
TTD: ARRY-162
- Version: 2020.06.01
Alternate Names:

D0C4LF TTD Drug ID

Drug Info:

Publications:

Akinleye A et al., 2013, MEK and the inhibitors: from bench to bedside., J Hematol Oncol

JAX-CKB: Binimetinib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Raja et al., 2015, Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer., Mol. Cancer Ther.

Bendell et al., 2017, A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor., Br. J. Cancer

Hamidi et al., 2014, KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition., Br. J. Cancer

JAX-CKB: MEK162

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Herkert et al., 2016, Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition., Cancer Res.

Gritsman et al., 2014, Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α., J. Clin. Invest.

Carita et al., 2016, Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma., Oncotarget

CIViC: BINIMETINIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Kopetz S et al., 2019, Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer., N Engl J Med

Dummer R et al., 2018, Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol

Thumar et al., 2014, MEK targeting in N-RAS mutated metastatic melanoma., Mol. Cancer

TALC: MEK162
- Version: 12-May-2016
Alternate Names:

MEK162 Primary Drug Name

MEK162 Drug Synonym

Drug Info:

Publications:
GuideToPharmacology: 249565604
- Version: 29-September-2020
Alternate Names:

BINIMETINIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
FDA: Binimetinib
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL3187723
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: MEK162
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL3187723
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
OncoKB: Binimetinib
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: MEK162
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
PharmGKB: binimetinib
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: MEK162
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:

combination therapy	MEK162 + AEB071
Indication/Tumor Type	uveal melanoma
Response Type	sensitive

combination therapy	BYL719 + MEK162
Indication/Tumor Type	acute myeloid leukemia
Response Type	sensitive

Novel drug target	Novel Target
Trial Name	ARRY-162
Specific Action of the Ligand	Negative

Mechanism of Interaction	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
Direct Interaction	yes
Specific Action of the Ligand	Negative

combination therapy	Encorafenib + Binimetinib
combination therapy	Encorafenib + Binimetinib + Cetuximab
Evidence Type	Actionable

Response Type	no benefit
Evidence Type	Actionable
Approval Status	Preclinical

Indication/Tumor Type	lung adenocarcinoma
Response Type	decreased response
Approval Status	Preclinical - Cell culture

Indication/Tumor Type	urinary bladder cancer
Response Type	predicted – sensitive
Indication/Tumor Type	Advanced Solid Tumor

Indication/Tumor Type	melanoma
Response Type	sensitive
Approval Status	Clinical Study

BINIMETINIB	DrugBank Drug Name
606143-89-9	CAS Number
Mektovi	Drug Brand

allosteric modulator
inhibitor (inhibitory)

allosteric modulator
inhibitor (inhibitory)

BINIMETINIB Drug Record

BINIMETINIB chembl:CHEMBL3187723 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial TTD

Interaction Types & Directionality: n/a

Interaction Info: combination therapy MEK162 + AEB071 Indication/Tumor Type uveal melanoma Response Type sensitive

PMIDs: 24141786 27507190

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy BYL719 + MEK162 Indication/Tumor Type acute myeloid leukemia Response Type sensitive

PMIDs: 24588908 28284557 27307593 23414587 29245078 28152546 11238126 24569456 26987942 28514312 26821351

Sources: OncoKB JAX-CKB CIViC

Interaction Types & Directionality: allosteric modulator inhibitor (inhibitory)

Interaction Info: Novel drug target Novel Target Trial Name ARRY-162 Specific Action of the Ligand Negative

PMIDs: 28587477

Sources: ClearityFoundationClinicalTrial MyCancerGenomeClinicalTrial TdgClinicalTrial DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 28587477

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: combination therapy MEK162 + AEB071 Indication/Tumor Type uveal melanoma Response Type predicted – sensitive

PMIDs: 27507190

Sources: JAX-CKB

Interaction Types & Directionality: allosteric modulator inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 1 inhibitor Direct Interaction yes Specific Action of the Ligand Negative

PMIDs: 31227518

Sources: ClearityFoundationClinicalTrial MyCancerGenomeClinicalTrial TdgClinicalTrial CIViC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26925841

Sources: ClearityFoundationBiomarkers CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Encorafenib + Binimetinib combination therapy Encorafenib + Binimetinib + Cetuximab Evidence Type Actionable

PMIDs: 27307593 23414587 31566309 28152546 29573941 26577700

Sources: ClearityFoundationBiomarkers OncoKB FDA PharmGKB JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info: Response Type no benefit Evidence Type Actionable Approval Status Preclinical

PMIDs: 26206338

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type lung adenocarcinoma Response Type decreased response Approval Status Preclinical - Cell culture

PMIDs: 32822286 26206338 28152546 25167228 27556948 27422710 27167191

Sources: ClearityFoundationBiomarkers OncoKB JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type urinary bladder cancer Response Type predicted – sensitive Indication/Tumor Type Advanced Solid Tumor

PMIDs: 26544513

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: FDA PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type melanoma Response Type sensitive Approval Status Clinical Study

PMIDs: 28514312

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial TTD

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MEK162 + AEB071

Indication/Tumor Type uveal melanoma

Response Type sensitive

PMIDs:
24141786 27507190

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BYL719 + MEK162

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

PMIDs:
24588908 28284557 27307593 23414587 29245078 28152546 11238126 24569456 26987942 28514312 26821351

Sources:
OncoKB JAX-CKB CIViC

Interaction Types & Directionality:

allosteric modulator

inhibitor (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name ARRY-162

Specific Action of the Ligand Negative

PMIDs:
28587477

Sources:
ClearityFoundationClinicalTrial MyCancerGenomeClinicalTrial TdgClinicalTrial DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
28587477

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MEK162 + AEB071

Indication/Tumor Type uveal melanoma

Response Type predicted – sensitive

PMIDs:
27507190

Sources:
JAX-CKB

Interaction Types & Directionality:

allosteric modulator

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 1 inhibitor

Direct Interaction yes

Specific Action of the Ligand Negative

PMIDs:
31227518

Sources:
ClearityFoundationClinicalTrial MyCancerGenomeClinicalTrial TdgClinicalTrial CIViC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
26925841

Sources:
ClearityFoundationBiomarkers CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Encorafenib + Binimetinib

combination therapy Encorafenib + Binimetinib + Cetuximab

Evidence Type Actionable

PMIDs:
27307593 23414587 31566309 28152546 29573941 26577700

Sources:
ClearityFoundationBiomarkers OncoKB FDA PharmGKB JAX-CKB CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type no benefit

Evidence Type Actionable

Approval Status Preclinical

PMIDs:
26206338

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung adenocarcinoma

Response Type decreased response

Approval Status Preclinical - Cell culture

PMIDs:
32822286 26206338 28152546 25167228 27556948 27422710 27167191

Sources:
ClearityFoundationBiomarkers OncoKB JAX-CKB CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type urinary bladder cancer

Response Type predicted – sensitive

Indication/Tumor Type Advanced Solid Tumor

PMIDs:
26544513

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
FDA PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Clinical Study

PMIDs:
28514312

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DrugBank

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BYL719 + MEK162

Indication/Tumor Type melanoma

Response Type no benefit

PMIDs:
26206338 26577700

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DrugBank

Alternate Names:

BINIMETINIB DrugBank Drug Name

606143-89-9 CAS Number

Mektovi Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Koelblinger P et al., 2017, A review of binimetinib for the treatment of mutant cutaneous melanoma., Future Oncol